Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02743078 | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | terminated | Phase 2 | 3 | RTOG Foundation, Inc.OTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02340156 | Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma | terminated | Phase 2 | 1 | SynerGene Therapeutics, Inc.INDUSTRY | 2 | Mar 3, 2021 | clinicaltrials |
| NCT02758366 |
| Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma |
| terminated |
| Phase 2 |
| 21 |
| Meyer Children's Hospital IRCCSOTHER |
| 1 |
| Feb 9, 2021 |
| clinicaltrials |
| NCT02296476 | A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) | terminated | Phase 2 | 12 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | terminated | Phase 1 / Phase 2 | 11 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01478321 | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | terminated | Phase 2 | 54 | Northwestern UniversityOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01349036 | A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma | terminated | Phase 2 | 38 | Daiichi SankyoINDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma(Toca5) | terminated | Phase 2 / Phase 3 | 403 | Tocagen Inc.INDUSTRY | 4 | Feb 7, 2020 | clinicaltrials |
| NCT02465528 | Ceritinib Rare Indications Study in ALK+ Tumors | terminated | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 27, 2019 | clinicaltrials |
| NCT01182350 | Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | terminated | Phase 2 | 53 | Karen D. Wright MDOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02395692 | Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2019 | clinicaltrials |
| NCT01186406 | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 41 | Duke UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01044966 | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02850744 | Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients | terminated | Phase 2 | 10 | PIQUR Therapeutics AGINDUSTRY | 1 | Oct 19, 2018 | clinicaltrials |
| NCT01575275 | Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme | terminated | Phase 2 | 8 | Michael Vogelbaum, MD, PhDOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | terminated | Phase 2 | 43 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jul 20, 2018 | clinicaltrials |
| NCT02227576 | Prevention of Thrombocytopenia in Glioblastoma Patients(PLATUM) | terminated | Phase 2 | 20 | University Hospital, LilleOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02654041 | Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients | terminated | Phase 2 | 3 | Musli Thyropeutics Ltd.INDUSTRY | 1 | Mar 22, 2018 | clinicaltrials |
| NCT02047214 | Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy | terminated | Phase 2 | 17 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01666600 | NOA-12: BIBF1120 and R-RT in Glioblastoma | terminated | Phase 1 / Phase 2 | 63 | Prof. Dr. Wolfgang WickOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT01508117 | Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | terminated | Phase 2 | 1 | University of CincinnatiOTHER | 1 | Sep 19, 2017 | clinicaltrials |
| NCT00112866 | Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme | terminated | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01310855 | Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 38 | University College, LondonOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01122901 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
| NCT00456612 | Radiosurgery for Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Deaconess Medical CenterOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00171938 | Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) | terminated | Phase 2 | 30 | NovartisINDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02025231 | Image Guided Reirradiation of High-grade Glioma | terminated | Phase 1 / Phase 2 | 31 | Rigshospitalet, DenmarkOTHER | 2 | Feb 8, 2017 | clinicaltrials |
| NCT02394665 | Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma | terminated | Phase 2 | 1 | University of MiamiOTHER | 1 | Jan 5, 2017 | clinicaltrials |
| NCT00574964 | Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme(Temodar) | terminated | Phase 2 | 50 | University of IowaOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT02060955 | Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan | terminated | Phase 2 | 25 | CytoVac A/SINDUSTRY | 1 | Jun 6, 2016 | clinicaltrials |
| NCT01351519 | A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors | terminated | Phase 2 | 16 | MultiCare Health System Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01189240 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | terminated | Phase 1 / Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Dec 14, 2015 | clinicaltrials |
| NCT01260467 | Memantine for Recurrent Glioblastoma | terminated | Phase 2 | 4 | University of RochesterOTHER | 1 | Dec 10, 2015 | clinicaltrials |
| NCT01778530 | TRC105 for Recurrent Glioblastoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Oct 7, 2015 | clinicaltrials |
| NCT00923117 | Sunitinib to Treat Recurrent Brain Cancer | terminated | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01898273 | Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma | terminated | Phase 2 | 7 | Cellectar Biosciences, Inc.INDUSTRY | 1 | Sep 9, 2015 | clinicaltrials |
| NCT01227434 | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma(PD0332991) | terminated | Phase 2 | 23 | University of California, San FranciscoOTHER | 1 | Jul 17, 2015 | clinicaltrials |
| NCT01205334 | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme(COGLI) | terminated | Phase 1 / Phase 2 | 2 | Baylor College of MedicineOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01095094 | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | terminated | Phase 2 | 19 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 10, 2013 | clinicaltrials |
| NCT01011231 | Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma(GKS) | terminated | Phase 2 | 1 | University of California, San FranciscoOTHER | 1 | May 6, 2013 | clinicaltrials |
| NCT00650949 | Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma | terminated | Phase 1 / Phase 2 | 20 | Gilead SciencesINDUSTRY | 1 | May 3, 2013 | clinicaltrials |
| NCT00959946 | Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 32 | PfizerINDUSTRY | 6 | Feb 22, 2013 | clinicaltrials |
| NCT00735436 | A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 18 | Duke UniversityOTHER | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00005856 | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00075491 | Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme | terminated | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00948389 | Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) | terminated | Phase 1 / Phase 2 | 28 | Bristol-Myers SquibbINDUSTRY | 4 | Aug 31, 2012 | clinicaltrials |
| NCT00790452 | Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jun 2, 2021source: clinicaltrials